Hypercalcemia

Hypercalcemia is an elevated serum calcium level, corrected for serum albumin — since roughly 40% of circulating calcium is protein-bound, total calcium falls when albumin is low even though the physiologically active ionized fraction has not changed. A practical bedside formula: corrected calcium (mmol/L) = measured total calcium (mmol/L) + [0.02 x (40 minus measured albumin in g/L)].^[1] Two hormones, parathyroid hormone (PTH) and vitamin D, normally hold serum calcium within a narrow range (roughly 2.10-2.60 mmol/L): PTH raises serum calcium by stimulating osteoclastic bone resorption, increasing renal calcium reabsorption, and driving renal activation of vitamin D to its active form (calcitriol), which in turn increases intestinal calcium absorption.^[2]

Hypercalcemia is staged by the corrected serum calcium level: mild under 3 mmol/L (under 12 mg/dL), moderate 3-3.5 mmol/L (12-14 mg/dL), and severe over 3.5 mmol/L (over 14 mg/dL).^[3] This numeric staging matters for treatment decisions, but the level alone does not reliably predict how symptomatic a given patient will be. The rate at which calcium rises matters as much as the absolute level reached — the severity of symptoms is not always related to the degree of hypercalcemia but often instead reflects the rapidity of onset, and the onset of hypercalcemia can itself be genuinely insidious.^[1] In practice, this means a patient with a chronically elevated but slowly progressive calcium from longstanding, mild primary hyperparathyroidism may be entirely asymptomatic at a level that would produce confusion or coma if reached rapidly from a malignant process — treat the trajectory, not only the number.

Primary hyperparathyroidism is the most common cause of hypercalcemia in ambulatory outpatients, typically producing a mild, slowly progressive elevation; it is covered in full in this platform's separate Hyperparathyroidism chapter and is deliberately not re-explained here. Malignancy is the most common cause in hospitalized and acutely unwell patients, typically producing a higher, more rapidly rising, and more symptomatic level.^[4][2] Together, these two causes account for over 90% of all hypercalcemia.^[4][2]

Hypercalcemia affects roughly 1% of the general population, though the figure is far higher in specific clinical settings. It is the most frequent metabolic emergency in oncology, occurring in 10-40% of people with cancer over the course of their disease, most commonly with advanced disease — where its presence is itself a marker of poor prognosis (see Special Populations).^[1] Tumours most often associated with malignancy-related hypercalcemia are multiple myeloma (40-50% of myeloma patients), breast cancer (over 20% of cancer-related hypercalcemia cases), and squamous-cell lung cancer (about 20%, occasionally adenocarcinoma, rarely small-cell); renal cell carcinoma and squamous-cell cancers of the head/neck and esophagus are also recognized associations. Hypercalcemia is rare or essentially never seen with prostate or colorectal cancer.^[1]

Stones, bones, groans, and psychiatric overtones

This classic mnemonic organizes the presentation, though patients rarely display every feature at once, symptoms may be entirely absent at mild severity, and the onset can be genuinely insidious.^[4][1]

Hypercalcemia is conventionally split into PTH-mediated and non-PTH-mediated causes — a distinction that maps directly onto the initial diagnostic test (see Assessment & Diagnosis).^[2]

History and physical examination

• Directed at etiology: medication review (lithium, thiazides, vitamin D and calcium supplements, antacids, teriparatide/abaloparatide), immobility, known or suspected malignancy, family history, and symptoms from each system above.
• Assess hydration status directly — most hypercalcemic patients are volume-depleted.
• Obtain an ECG when clinically indicated — severe hypercalcemia, any symptomatic presentation, or concurrent digoxin therapy — looking for a shortened QT interval, a prolonged PR interval, a widened QRS complex, or bradyarrhythmia.^[1]

Confirm and stage

Confirm with a corrected (albumin-adjusted) total calcium, or with an ionized calcium directly where available — ionized calcium is not affected by albumin and is the more reliable measure in a patient with significant hypoalbuminemia or a critical illness. Stage severity as mild, moderate, or severe (see Clinical Snapshot), and estimate the rate of rise from any prior calcium values on record.^[1][3]

PTH — the key initial test

Measure intact PTH first, before further workup — it is the single test that most efficiently separates the two major diagnostic pathways.^[2][4]

• PTH elevated, or inappropriately normal (i.e., not appropriately suppressed given the elevated calcium) points to a PTH-mediated cause — most often primary hyperparathyroidism. A 24-hour urinary calcium helps distinguish primary hyperparathyroidism (high urinary calcium) from the much rarer familial hypocalciuric hypercalcemia (low urinary calcium). See this platform's separate Hyperparathyroidism chapter for the full diagnostic and management pathway from this point.^[2]
• PTH suppressed points to a non-PTH-mediated cause, most often malignancy, and directs further testing:
  • PTHrP — order specifically when malignancy is suspected; an elevated level confirms humoral hypercalcemia of malignancy.^[2][1]
  • 25-hydroxyvitamin D — markedly elevated in vitamin D toxicity/excess supplementation.^[4]
  • 1,25-dihydroxyvitamin D (calcitriol) — elevated (with a normal or low 25-hydroxyvitamin D) in calcitriol-mediated hypercalcemia from lymphoma or granulomatous disease such as sarcoidosis.^[2][4]

Supportive and additional testing

• Serum albumin — required to interpret total calcium correctly.^[1]
• Alkaline phosphatase — usually elevated with increased bone turnover, except characteristically normal in multiple myeloma.^[1]
• Serum chloride — may be elevated in primary hyperparathyroidism (an elevated chloride-to-phosphate ratio is a classic, if now rarely used, supportive finding).^[1]
• BUN and creatinine — may be elevated from hypercalcemia-related renal impairment, and are also needed before any bisphosphonate dose (see Choose Initial Treatment).^[1]
• Serum/urine protein electrophoresis, thyroid function testing, and imaging directed at a suspected malignancy where the cause remains unclear after initial workup.^[2]

• Acutely lower serum calcium to a safe level and control symptoms — the immediate priority in any moderate-severe or symptomatic presentation.
• Restore intravascular volume, since dehydration both accompanies and perpetuates hypercalcemia.
• Identify and treat the underlying cause rather than treating the number in isolation — stopping a causative drug, treating the underlying malignancy, or referring for parathyroidectomy where appropriate.
• In malignancy-associated hypercalcemia specifically, situate acute treatment within the patient's overall goals of care rather than treating reflexively (see Special Populations).
• Avoid iatrogenic harm from treatment itself — volume overload from overly aggressive rehydration, hypocalcemia from bisphosphonate or denosumab overshoot, and renal toxicity from bisphosphonate therapy given without adequate hydration or in significant renal impairment.

• Mobilization — encourage and support ambulation wherever possible; immobility itself increases osteoclastic bone resorption and worsens hypercalcemia, especially in a patient with an already high bone-turnover state.^[1]
• Increase oral fluid intake to roughly 2-3 litres per day as tolerated, for a patient able to take fluids by mouth and with mild or borderline hypercalcemia — this alone may be sufficient at this severity.^[1]
• Stop or hold any drug contributing to hypercalcemia — thiazide diuretics, lithium (in consultation with the prescriber, given the need to weigh psychiatric stability), vitamin D and calcium supplements, calcium-containing antacids, and, less commonly, H2-receptor antagonists.^[1]
• A low-calcium diet is not useful for the acute management of hypercalcemia — it is unpalatable, impractical, worsens nutritional status in an already unwell patient, and has essentially no role even in the specific setting of calcitriol-mediated hypercalcemia where dietary calcium restriction might seem intuitive.^[1]
• Patient and caregiver education — for anyone at recognized risk (known malignancy, primary hyperparathyroidism, chronic lithium therapy, high-dose vitamin D supplementation), teach the early signs and symptoms of rising calcium to promote prompt recognition of an acute rise before it becomes severe.^[1]

Malignancy-associated hypercalcemia and goals of care

Malignancy-associated hypercalcemia most commonly arises with advanced cancer and is itself a marker of poor prognosis.^[1] Whether or not the underlying malignancy can itself be treated, every patient benefits from symptom-focused management of the hypercalcemia — education, hydration, and medication as above — but whether aggressive correction is appropriate at all depends on the patient's overall goals of care, not on the calcium level alone. An evident, treatable cause does not automatically mean treatment is indicated once the stage of the underlying disease is considered; this decision belongs to the patient (or substitute decision-maker) together with the treating team, ideally raised proactively rather than only in a crisis.^[1] Pharmacists are well placed to flag when hypercalcemia treatment is being escalated (e.g., a second bisphosphonate cycle, then denosumab) without an apparent parallel conversation about the patient's overall trajectory and wishes.

Renal impairment

Renal impairment affects both the choice and the dosing of hypercalcemia therapy. Zoledronic acid requires no dose reduction for mild-moderate impairment in this specific indication but is not recommended in severe renal impairment; pamidronate remains an option with a longer infusion time. Denosumab requires no renal dose adjustment and is often the preferred choice once renal impairment is significant, but carries a genuinely elevated hypocalcemia risk in severe impairment or dialysis, requiring closer calcium monitoring.^[5][6] Loop diuretics should still not be added routinely regardless of renal status, for the same reasons as in a patient with normal renal function.

Pregnancy and breastfeeding

Bisphosphonates (zoledronic acid, pamidronate) are contraindicated in pregnancy and breastfeeding per the Canadian product monograph, reflecting their long skeletal retention and theoretical risk to fetal bone development.^[5] IV isotonic saline remains appropriate and safe. Hypercalcemia in pregnancy is uncommon and should prompt investigation for an underlying cause (most often primary hyperparathyroidism) and specialist involvement rather than routine bisphosphonate use.

Older adults

Older adults are both more likely to develop clinically significant hypercalcemia (higher background prevalence of malignancy and primary hyperparathyroidism, more frequent thiazide use) and more vulnerable to its cardiac and neuropsychiatric effects. Rehydration rate should be adjusted more conservatively in a patient with reduced cardiac reserve, and a new confusion, constipation, or functional decline in an older adult can be the presenting complaint rather than thirst or the classic symptoms.

Pediatrics

Hypercalcemia in children is uncommon and etiology differs meaningfully from the adult pattern (e.g., subcutaneous fat necrosis of the newborn, Williams syndrome, and immobilization-associated hypercalcemia in a rapidly growing, immobilized adolescent skeleton are more prominent). Dosing for calcitonin, bisphosphonates, and denosumab in children is not established in the sources for this chapter and requires pediatric endocrinology direction.

• Recheck serum calcium, electrolytes, urea, and creatinine on day 3 after any IV bisphosphonate dose, and again as clinically indicated while calcium continues to trend toward normal.^[1]
• Measure serum creatinine before every bisphosphonate dose; withhold or adjust further dosing if renal function has deteriorated from baseline.^[5]
• Monitor serum calcium closely during and after calcitonin therapy, watching specifically for tachyphylaxis (a diminishing response) if treatment extends beyond 48-72 hours.
• After denosumab, check calcium within 2 weeks of each dose — more frequently, and for longer, in a patient with severe renal impairment or on dialysis, given the elevated hypocalcemia risk in this population.^[6]
• Continuous ECG monitoring during treatment of any severe or symptomatic hypercalcemia, and in any patient also taking digoxin.
• Once the acute episode has resolved, follow up on the underlying cause identified — confirm a causative drug has genuinely been stopped (or reassessed with the prescriber), confirm oncology follow-up is in place for a malignancy-associated case, or refer for parathyroidectomy assessment where primary hyperparathyroidism was the cause (see the separate Hyperparathyroidism chapter).

1. Hypercalcemia not falling as expected after adequate IV fluids and a bisphosphonate: reconfirm the patient was genuinely well-hydrated before and during bisphosphonate administration, and rule out an unrecognized ongoing source (e.g., an unaddressed vitamin D or calcium supplement, or a continuing thiazide).
2. Reassess renal function — both the cause of poor response (underlying renal impairment blunting bisphosphonate efficacy) and a consequence to monitor for (bisphosphonate-related renal deterioration).
3. Confirmed refractory hypercalcemia after an adequate trial of IV bisphosphonate: move to denosumab.^[3][6]
4. Severe, refractory hypercalcemia, particularly with concurrent renal failure limiting other options: escalate to dialysis using a low- or no-calcium dialysate.^[2]
5. Calcitonin's effect fading within the expected 48-72 hour window: this is expected tachyphylaxis, not treatment failure requiring dose escalation — the bisphosphonate given alongside it should be taking over by this point.
6. Recurrent hypercalcemia after initial successful treatment: reassess the underlying cause — progression of the underlying malignancy, an unaddressed causative drug, or a missed alternative diagnosis (e.g., previously subclinical primary hyperparathyroidism unmasked by a thiazide) — rather than simply repeating the same acute treatment indefinitely.

• Giving an IV bisphosphonate before the patient is adequately rehydrated — both reduces efficacy and increases renal toxicity risk.
• Adding a loop diuretic routinely alongside rehydration — outdated practice with little supporting evidence and a real risk of worsening volume/electrolyte depletion.
• Continuing calcitonin beyond 48-72 hours expecting a sustained effect — tachyphylaxis is expected, not a sign of an inadequate dose.
• Treating the numeric calcium level in isolation without considering the rate of rise — a rapidly rising level can be dangerous well before it reaches the "severe" numeric threshold.
• Missing a reversible drug-induced cause — thiazide diuretics, lithium, and over-the-counter vitamin D supplementation are common, genuinely modifiable contributors.
• Giving the standard 4 mg zoledronic acid dose in a patient with severe renal impairment, where it is not recommended, rather than considering pamidronate or denosumab instead.
• Assuming denosumab is first-line therapy in Canada — the Canadian product monograph's approved indication is specifically bisphosphonate-refractory hypercalcemia of malignancy, narrower than some international guidance.
• Escalating hypercalcemia treatment in advanced malignancy without an explicit goals-of-care conversation.
• Ordering PTHrP or vitamin D studies before checking PTH — PTH is the efficient first test that determines which further workup is actually needed.
• Attributing new confusion or functional decline in an older adult to "just getting older" rather than checking a calcium level.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Intravenous Fluids

Foundational first-line therapy for moderate-severe or symptomatic hypercalcemia — restores volume and promotes renal calcium excretion.

Loop Diuretics

Not routinely recommended alongside rehydration — reserve for volume overload developing during treatment.

Calcitonin

Rapid-onset, short-duration bridge while awaiting bisphosphonate effect; always given together with a bisphosphonate, never as sole therapy beyond the acute window.

Bisphosphonates, Intravenous

The mainstay of treatment for moderate-severe or malignancy-associated hypercalcemia. Give only after adequate rehydration with a satisfactory urine output. Delayed onset (roughly 48-72 hours) but a considerably more sustained effect than calcitonin.

RANKL Inhibitor

For hypercalcemia refractory to an IV bisphosphonate, or when significant renal impairment makes a bisphosphonate relatively unsuitable. No renal dose adjustment required, but hypocalcemia risk is genuinely elevated with severe renal impairment or dialysis.

Glucocorticoids

For calcitriol-mediated hypercalcemia specifically (lymphoma, granulomatous disease such as sarcoidosis) — reduces macrophage/lymphocyte conversion of vitamin D to calcitriol. Not a substitute for a bisphosphonate in other hypercalcemia etiologies.